Apellis Pharmaceuticals Inc [APLS] stock is trading at $29.78, up 5.72%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The APLS shares have gain 10.01% over the last week, with a monthly amount glided 33.12%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Apellis Pharmaceuticals Inc [NASDAQ: APLS] stock has seen the most recent analyst activity on October 15, 2025, when Wells Fargo initiated its Overweight rating and assigned the stock a price target of $32. Previously, Goldman downgraded its rating to Sell on September 26, 2025, and kept the price target unchanged to $18. On May 09, 2025, downgrade downgraded it’s rating to Outperform but maintained its price target of $52 on the stock. BofA Securities downgraded its rating to a Neutral but stick to its price target of $23 on May 09, 2025. Cantor Fitzgerald initiated its recommendation with a Overweight and recommended $44 as its price target on April 29, 2025. Goldman downgraded its rating to Neutral for this stock on December 17, 2024, but kept the price target unchanged to $36. In a note dated November 21, 2024, Morgan Stanley initiated an Equal-Weight rating and provided a target price of $31 on this stock.
Apellis Pharmaceuticals Inc [APLS] stock has fluctuated between $16.10 and $35.72 over the past year. Currently, Wall Street analysts expect the stock to reach $24 within the next 12 months. Apellis Pharmaceuticals Inc [NASDAQ: APLS] shares were valued at $29.78 at the most recent close of the market. An investor can expect a potential drop of -19.41% based on the average APLS price forecast.
Analyzing the APLS fundamentals
Apellis Pharmaceuticals Inc [NASDAQ:APLS] reported sales of 754.65M for the trailing twelve months, which represents a drop of -10.61%. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at -0.25%, Pretax Profit Margin comes in at -0.3%, and Net Profit Margin reading is -0.3%. To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -1.16 and Total Capital is -0.31. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 3.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 28.71 points at the first support level, and at 27.64 for the second support level. However, for the 1st resistance point, the stock is sitting at 30.36, and for the 2nd resistance point, it is at 30.93.
Ratios To Look Out For
For context, Apellis Pharmaceuticals Inc’s Current Ratio is 3.77. Also, the Quick Ratio is 3.16, while the Cash Ratio stands at 1.85. Considering the valuation of this stock, the price to sales ratio is 4.98, the price to book ratio is 24.04.
Transactions by insiders
Recent insider trading involved Sullivan Timothy Eugene, Chief Financial Officer, that happened on Oct 21 ’25 when 10000.0 shares were sold. Officer, Sullivan Timothy Eugene completed a deal on Oct 21 ’25 to buy 10000.0 shares. Meanwhile, General Counsel Watson David O. sold 5000.0 shares on Oct 16 ’25.
